Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Heart Journal

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurheartj/ehn277PMID 18586661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mineralocorticoid Receptor Blockade Improves Vasomotor Dysfunction and Vascular Oxidative Stress Early After Myocardial Infarction

  2007cited by this paper
• Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

  2007cited by this paper
• Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.

  2007cited by this paper
• Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity

  2006cited by this paper
• Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats

  2006cited by this paper
• Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure

  2006cited by this paper
• Triple ACE-ECE-NEP Inhibition in Heart Failure: A Comparison With ACE and Dual ECE-NEP Inhibition

  2005cited by this paper
• Nongenomic Effects of Aldosterone in the Human Heart: Interaction With Angiotensin II

  2005cited by this paper
• Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage

  2005cited by this paper
• Aldosterone Stimulates Matrix Metalloproteinases and Reactive Oxygen Species in Adult Rat Ventricular Cardiomyocytes

  2005cited by this paper
• Aldosterone Nongenomically Worsens Ischemia Via Protein Kinase C-Dependent Pathways in Hypoperfused Canine Hearts

  2005cited by this paper
• Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients

  2005cited by this paper
• Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure.

  2005cited by this paper
• Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.

  2005cited by this paper
• Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels.

  2005cited by this paper
• The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction

  2004cited by this paper
• Aldosterone Administration to Mice Stimulates Macrophage NADPH Oxidase and Increases Atherosclerosis Development: A Possible Role for Angiotensin-Converting Enzyme and the Receptors or Angiotensin II and Aldosterone

  2004cited by this paper
• Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

  2004cited by this paper
• Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy.

  2004cited by this paper
• Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure

  2004cited by this paper
• Role of reactive oxygen species in cocaine-induced cardiac dysfunction.

  2003cited by this paper
• Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression.

  2003cited by this paper
• Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.

  2003cited by this paper
• Rapid Inhibition of Vasoconstriction in Renal Afferent Arterioles by Aldosterone

  2003cited by this paper
• Nongenomic vascular action of aldosterone in the glomerular microcirculation.

  2003cited by this paper
• Aldosterone Regulates Vascular Reactivity: Short-Term Effects Mediated by Phosphatidylinositol 3-Kinase–Dependent Nitric Oxide Synthase Activation

  2003cited by this paper
• NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection.

  2003cited by this paper
• Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression.

  2002cited by this paper
• Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.

  2002cited by this paper
• Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats

  2002cited by this paper
• Long-Term Survival and Hemodynamics After Endothelin-A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition in Rats With Chronic Heart Failure: Monotherapy Versus Combination Therapy

  2002cited by this paper
• Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.

  2002cited by this paper
• Beneficial Effects of Long-Term Use of the Antioxidant Probucol in Heart Failure in the Rat

  2002cited by this paper
• Oxygen Reduction by Nitric-oxide Synthases*

  2001cited by this paper
• Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.

  2001cited by this paper
• Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

  1999cited by this paper
• , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies.

  1996cited by this paper
• Ventricular remodeling after myocardial infarction.

  1993cited by this paper
• Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications

  1990cited by this paper
• Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements

  1978cited by this paper
• Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.

  1977cited by this paper

• Aldosterone synthase inhibitors across the translational spectrum: Mechanistic foundations and emerging clinical applications

  2026cites this paper
• Aldosterone synthase inhibition: a novel bullet to fight cardiovascular-kidney metabolic syndrome.

  2025cites this paper
• Dual ETA‐ETB receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction

  2025cites this paper
• Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.

  2024cites this paper
• Aldosterone and Aldosterone Synthase Inhibitors in Cardiorenal Disease.

  2023cites this paper
• The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes

  2023cites this paper
• Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

  2022cites this paper
• MINI-FOCUS: INFLAMMATION IN CARDIAC INJURY The IL-1b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

  2022cites this paper
• Atrial fibrillation in heart failure patients: An update on renin–angiotensin–aldosterone system pathway blockade as a therapeutic and prevention target

  2022cites this paper
• Recent Advances Toward New Small Molecule Therapies for Heart Failure

  2021cites this paper
• Transient heart rate reduction improves acute decompensated heart failure‐induced left ventricular and coronary dysfunction

  2021cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonism for cardiovascular and renal disorders - new perspectives for combination therapy.

  2021cites this paper
• Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies

  2021cites this paper
• Plasma aldosterone and atrial mitochondrial functions of patients undergoing cardiac surgery.

  2020cites this paper
• Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

  2020cites this paper
• Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome

  2020cites this paper
• Nitrogen Dioxide Inhalation Exposures Induce Cardiac Mitochondrial Reactive Oxygen Species Production, Impair Mitochondrial Function and Promote Coronary Endothelial Dysfunction

  2020cites this paper
• Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model

  2019cites this paper
• The role of aldosterone and mineralocorticoid receptor antagonists in cardiovascular damage

  2019cites this paper
• Aldosterone/MR Signaling, Oxidative Stress, and Vascular Dysfunction

  2019cites this paper
• Future Anti-aldosterone Agents.

  2019cites this paper
• Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity.

  2018cites this paper
• The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction

  2018cites this paper
• Protein tyrosine phosphatase 1B inactivation limits aging-associated heart failure in mice.

  2018cites this paper
• Exercise training induces eNOS coupling and restores relaxation in coronary arteries of heart failure rats.

  2018cites this paper
• Newer hormonal pharmacotherapies for heart failure

  2018cites this paper
• Short‐ and long‐term administration of the non‐steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome‐related cardio‐renal dysfunction

  2018cites this paper
• Treatments for Heart Failure

  2017cites this paper
• The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?

  2017cites this paper
• The IL-1 b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

  2017cites this paper
• The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

  2017cites this paper
• The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice

  2017cites this paper
• 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures.

  2017cites this paper
• Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction

  2016cites this paper
• Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.

  2016cites this paper
• Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease

  2016cites this paper
• Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies

  2016cites this paper
• Pharmacology of heart failure: From basic science to novel therapies.

  2016cites this paper
• New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?

  2016cites this paper
• The search for efficient diagnostic and prognostic biomarkers of heart failure.

  2016cites this paper
• Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload.

  2016cites this paper
• The Renin-Angiotensin-Aldosterone System in Cardiovascular Diseases

  2015cites this paper
• Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.

  2015cites this paper
• ZSF1 rat: a model of chronic cardiac and renal diseases in the context of metabolic syndrome. Characterization with anti-oxidant, mineralocorticoid receptor antagonist and aldosterone synthase inhibitor

  2015cites this paper
• Heart failure: Novel therapeutic approaches

  2015cites this paper
• Selective Heart Rate Reduction Improves Metabolic Syndrome–related Left Ventricular Diastolic Dysfunction

  2015cites this paper
• Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.

  2015cites this paper
• Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.

  2015cites this paper
• Novel RAAS agonists and antagonists: clinical applications and controversies

  2015cites this paper
• Enhanced nitric oxide bioavailability in coronary arteries prevents the onset of heart failure in rats with myocardial infarction.

  2015cites this paper
• Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.

  2015cites this paper
• Mineralocorticoids in the heart and vasculature: new insights for old hormones.

  2015cites this paper
• Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

  2015cites this paper
• Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide

  2014cites this paper
• Interfering with mineralocorticoid receptor activation: the past, present, and future

  2014cites this paper
• The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling

  2014cites this paper
• Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy

  2014cites this paper
• Aldosterone and Cardiovascular Diseases

  2014cites this paper
• Implication de la Lipocaline 2 dans les effets physiopathologiques du récepteur minéralocorticoïde dans le système cardiovasculaire.

  2014cites this paper
• Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives

  2014cites this paper
• Aldosterone synthase inhibitors in cardiovascular and renal diseases.

  2014cites this paper
• Comparison of agents that affect aldosterone action.

  2014cites this paper
• The cardioprotective effects of mineralocorticoid receptor antagonists.

  2014cites this paper
• Heart Failure and Mitochondrial Dysfunction: The Role of Mitochondrial Fission/Fusion Abnormalities and New Therapeutic Strategies

  2014cites this paper
• Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents

  2014influential citation
• New antihypertensive drugs under development.

  2014cites this paper
• Entwicklung von Teststrategien zur selektiven Hemmung von Enzymen der adrenalen Steroidsynthese unter besonderer Berücksichtigung von Speziesunterschieden

  2014cites this paper
• Targeting cardiac hypertrophy: toward a causal heart failure therapy.

  2014cites this paper
• Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.

  2014cites this paper
• Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.

  2014cites this paper
• Aldosterone synthase inhibitors in hypertension: current status and future possibilities

  2014cites this paper
• Primary Aldosteronism

  2014cites this paper
• Update sui biomarcatori nello scompenso cardiaco

  2013cites this paper
• Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

  2013cites this paper
• Circulating plasma serine208-phosphorylated troponin T levels are indicator of cardiac dysfunction

  2013cites this paper
• ENaC modulators and renal disease.

  2013cites this paper
• Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo

  2013cites this paper
• Role of mineralocorticoid receptor regulation during experimental myocardial infarction

  2013cites this paper
• Aldosterone and cardiovascular disease: the heart of the matter.

  2013cites this paper
• Pathological Ventricular Remodeling: Mechanisms Part 1 of 2

  2013cites this paper
• Aldosterone synthase inhibition in humans.

  2013cites this paper
• Pathological Ventricular Remodeling: Therapies Part 2 of 2

  2013cites this paper
• Aldosterone Synthase Inhibition in Hypertension

  2013cites this paper
• MR relaxometry and perfusion of the myocardium in spontaneously hypertensive rat: correlation with histopathology and effect of anti-hypertensive therapy

  2013cites this paper
• The Transition from Hypertensive Hypertrophy to Left Ventricular Systolic Chamber Decompensation

  2013influential citation
• Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.

  2013cites this paper
• Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction

  2012cites this paper
• Noncanonical mechanisms to regulate nuclear receptor signaling.

  2012cites this paper
• Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances

  2012cites this paper
• Platt versus Pickering: what molecular insight to primary hyperaldosteronism tells us about hypertension

  2012cites this paper
• Heart Rate Reduction Induced by the If Current Inhibitor Ivabradine Improves Diastolic Function and Attenuates Cardiac Tissue Hypoxia

  2012cites this paper
• Aldosterone, mineralocorticoid receptor, and heart failure.

  2012cites this paper
• Novel therapies in acute and chronic heart failure.

  2012cites this paper
• Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury

  2012cites this paper
• Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.

  2012cites this paper
• 3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2

  2012cites this paper
• Le rôle de l’aldostérone sur le remodelage structurel pulmonaire et la fonction ventriculaire droite en insuffisance cardiaque congestive

  2012cites this paper
• Identification de nouvelles options thérapeutiques et diagnostiques dans l'hyperaldostéronisme primaire

  2012cites this paper
• Neovascularization Is Attenuated With Aldosterone Synthase Inhibition in Rats With Retinopathy

  2012cites this paper
• Estudo da função em artérias de resistência de ratos pós-infarto do miocárdio.

  2012cites this paper